HRP20201923T1 - Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije - Google Patents
Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije Download PDFInfo
- Publication number
- HRP20201923T1 HRP20201923T1 HRP20201923TT HRP20201923T HRP20201923T1 HR P20201923 T1 HRP20201923 T1 HR P20201923T1 HR P20201923T T HRP20201923T T HR P20201923TT HR P20201923 T HRP20201923 T HR P20201923T HR P20201923 T1 HRP20201923 T1 HR P20201923T1
- Authority
- HR
- Croatia
- Prior art keywords
- amount
- fatty acids
- formulation
- medium
- weight
- Prior art date
Links
- 229960003088 loratadine Drugs 0.000 title claims 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims 4
- 238000005538 encapsulation Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 4
- -1 triglyceride fatty acids Chemical class 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- YOYOQXRPUDEPAK-UHFFFAOYSA-N 1-Hydroxy-3-(octanoyloxy)propan-2-yl decanoate Chemical compound CCCCCCCCCC(=O)OC(CO)COC(=O)CCCCCCC YOYOQXRPUDEPAK-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 229920003078 Povidone K 12 Polymers 0.000 claims 1
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Farmaceutska formulacija loratadina, naznačena time da sadrži:
loratadin u količini u rasponu od 3% do 7% masenog udjela;
jednu ili više mono- i di-gliceridinih masnih kiselina srednjeg lanca u količini od 33% do 83% masenog udjela, pri ćemu mono- i di-gliceridne masne kiseline srednjeg lanca su gliceril mono- & dikaprat;
jednu ili više masnih kiselina srednjeg lanca triglicerida u količini od 8% do 50% masenog udjela; disperzent je povidon; i
surfaktant u količini od 2% do 5% masenog udjela, pri čemu je surfaktant polioksietilen sorbitan ester masne kiseline, koji je polisorbat 80;
pri čemu je omjer količine disperzenata u količini surfaktanata 1,75:1 do 2,5:1;
pri čemu je tekuća formulacija pogodna za kapsuliranje u obliku doziranja mekane gel-kapsule ispunjene tekućinom; a gdje je povidon povidon K-12.
2. Formulacija prema zahtjevu 1, naznačena time da nadalje sadrži vodu.
3. Formulacija u skladu s patentnim zahtjevom 2, naznačena time da se količina vode kreće od 1% do 4% masenog udjela.
4. Formulacija u skladu s patentnim zahtjevom 1, naznačena time da su masne kiseline srednjeg lanca triglicerida odabrane iz skupine koja se sastoji od gliceril trikaprilata/kaprata, glicerol kaprilata kaprata i kapril/kapri triglicerida.
5. Formulacija prema zahtjevu 1, naznačena time da formulacija ima vrijednost hidrofilne lipofilne ravnoteže (HLB) između 3 i 7, posebno između 5 i 6.
6. Formulacija u skladu s patentnim zahtjevom 1, naznačena time da masne kiseline srednjeg monoglicerida imaju vrijednost HLB između 5 i 6, a masne kiseline srednjeg lanca triglicerida imaju vrijednost HLB od 11.
7. Formulacija prema zahtjevu 1, naznačena time da površinsko aktivno sredstvo ima HLB vrijednost između 14 i 17.
8. Oblik doziranja loratadina za oralnu primjenu, naznačen time da sadrži:
nosač za davanje lijeka; i
formulaciju za punjenje prema bilo kojem od zahtjeva 1 do 7 smještenu u nosaču za dostavu lijeka.
9. Oblik doziranja prema zahtjevu 8, naznačen time da je sredstvo za davanje lijeka kapsula, mekana želatinska kapsula ili kapsula koja se uglavnom sastoji od želatine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2690490A CA2690490C (en) | 2010-01-19 | 2010-01-19 | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| EP11734280.8A EP2525827B1 (en) | 2010-01-19 | 2011-01-18 | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| PCT/CA2011/000052 WO2011088550A1 (en) | 2010-01-19 | 2011-01-18 | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201923T1 true HRP20201923T1 (hr) | 2021-02-05 |
Family
ID=44303619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201923TT HRP20201923T1 (hr) | 2010-01-19 | 2020-12-02 | Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120301544A1 (hr) |
| EP (2) | EP2525827B1 (hr) |
| JP (1) | JP5328992B2 (hr) |
| AU (1) | AU2011207058B2 (hr) |
| CA (1) | CA2690490C (hr) |
| CY (1) | CY1123895T1 (hr) |
| DK (1) | DK2525827T3 (hr) |
| ES (1) | ES2843351T3 (hr) |
| HR (1) | HRP20201923T1 (hr) |
| HU (1) | HUE053412T2 (hr) |
| LT (1) | LT2525827T (hr) |
| MX (1) | MX344163B (hr) |
| PL (1) | PL2525827T3 (hr) |
| PT (1) | PT2525827T (hr) |
| RS (1) | RS61362B1 (hr) |
| SI (1) | SI2525827T1 (hr) |
| WO (1) | WO2011088550A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784446B (zh) * | 2014-03-05 | 2016-01-06 | 大连金石滩药业有限公司 | 氯雷他定组合物 |
| CN103784399B (zh) * | 2014-03-05 | 2015-09-30 | 大连金石滩药业有限公司 | 氯雷他定液体组合物 |
| JP7065562B2 (ja) * | 2015-09-04 | 2022-05-12 | ロート製薬株式会社 | 医薬組成物 |
| KR101746500B1 (ko) | 2016-05-26 | 2017-06-14 | (주)알피바이오 | 연질캡슐 제제용 로라타딘 조성물 및 이를 함유하는 연질캡슐 |
| WO2019113461A1 (en) | 2017-12-08 | 2019-06-13 | Western University Of Health Sciences | Lipid emulsified drug delivery systems for chemoprevention and treatment |
| CA3100314A1 (en) | 2018-05-16 | 2019-11-21 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
| CN112426404B (zh) * | 2020-10-29 | 2023-02-28 | 太阳升(亳州)生物医药科技有限公司 | 用于制备富马酸卢帕他定口服液的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| WO1985003707A1 (en) | 1984-02-15 | 1985-08-29 | Schering Corporation | 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US4910205A (en) | 1988-05-02 | 1990-03-20 | Schering Corporation | Transdermal delivery of loratadine |
| US4863931A (en) | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| ES2093269T3 (es) * | 1991-07-26 | 1996-12-16 | Smithkline Beecham Corp | Microemulsiones del tipo agua en aceite. |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
| US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| PL315635A1 (en) * | 1994-01-24 | 1996-11-25 | Procter & Gamble | Method of solubilising hardly pharmaceutically active substances |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| CN1145030A (zh) * | 1994-04-07 | 1997-03-12 | 史密丝克莱恩比彻姆有限公司 | 用于治疗疟疾的氯氟菲醇游离碱及组合物 |
| US5595997A (en) | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| DE69940769D1 (de) * | 1998-01-20 | 2009-06-04 | Applied Analytical Ind Inc | Orale flüssige zusammensetzungen |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| ATE274907T1 (de) | 1998-06-30 | 2004-09-15 | Pfizer Prod Inc | Loratadin zur verwendung als antiarrhythmikum |
| US6221391B1 (en) * | 1998-11-23 | 2001-04-24 | Accucaps Industries Limited | Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| US6720002B2 (en) | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
| DE60222803T2 (de) * | 2001-12-21 | 2008-07-17 | Supernus Pharmaceuticals, Inc. | Orale kapselformulierung mit verbesserter physikalischer stabilität |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| KR100533460B1 (ko) * | 2002-07-20 | 2005-12-08 | 대화제약 주식회사 | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 |
| RU2007139819A (ru) * | 2005-03-29 | 2009-05-10 | МакНЕЙЛ-Пи-Пи-Си, ИНК. (US) | Композиции с гидрофильными лекарствами в гидрофобной среде |
| US20110020440A1 (en) * | 2007-11-19 | 2011-01-27 | Cadila Pharmaceuticals Limited | Stable solutions of sparingly soluble actives |
-
2010
- 2010-01-19 CA CA2690490A patent/CA2690490C/en active Active
-
2011
- 2011-01-18 PL PL11734280T patent/PL2525827T3/pl unknown
- 2011-01-18 ES ES11734280T patent/ES2843351T3/es active Active
- 2011-01-18 LT LTEP11734280.8T patent/LT2525827T/lt unknown
- 2011-01-18 PT PT117342808T patent/PT2525827T/pt unknown
- 2011-01-18 US US13/574,189 patent/US20120301544A1/en active Pending
- 2011-01-18 DK DK11734280.8T patent/DK2525827T3/da active
- 2011-01-18 SI SI201131943T patent/SI2525827T1/sl unknown
- 2011-01-18 EP EP11734280.8A patent/EP2525827B1/en active Active
- 2011-01-18 EP EP19217776.4A patent/EP3653204A1/en active Pending
- 2011-01-18 MX MX2012008301A patent/MX344163B/es active IP Right Grant
- 2011-01-18 WO PCT/CA2011/000052 patent/WO2011088550A1/en active Application Filing
- 2011-01-18 HU HUE11734280A patent/HUE053412T2/hu unknown
- 2011-01-18 AU AU2011207058A patent/AU2011207058B2/en active Active
- 2011-01-18 RS RS20210013A patent/RS61362B1/sr unknown
- 2011-01-18 JP JP2012549213A patent/JP5328992B2/ja not_active Expired - Fee Related
-
2020
- 2020-12-02 HR HRP20201923TT patent/HRP20201923T1/hr unknown
-
2021
- 2021-01-13 CY CY20211100020T patent/CY1123895T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX344163B (es) | 2016-12-07 |
| SI2525827T1 (sl) | 2021-02-26 |
| HUE053412T2 (hu) | 2021-06-28 |
| RS61362B1 (sr) | 2021-02-26 |
| US20120301544A1 (en) | 2012-11-29 |
| EP2525827A4 (en) | 2014-04-30 |
| AU2011207058A1 (en) | 2012-09-06 |
| AU2011207058B2 (en) | 2015-04-23 |
| PL2525827T3 (pl) | 2021-05-04 |
| EP3653204A1 (en) | 2020-05-20 |
| ES2843351T3 (es) | 2021-07-16 |
| PT2525827T (pt) | 2021-01-20 |
| WO2011088550A1 (en) | 2011-07-28 |
| EP2525827B1 (en) | 2020-11-18 |
| MX2012008301A (es) | 2012-09-28 |
| DK2525827T3 (da) | 2020-12-14 |
| CA2690490C (en) | 2012-06-26 |
| LT2525827T (lt) | 2021-03-25 |
| JP2013517303A (ja) | 2013-05-16 |
| JP5328992B2 (ja) | 2013-10-30 |
| CA2690490A1 (en) | 2011-07-19 |
| CY1123895T1 (el) | 2022-05-27 |
| EP2525827A1 (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201923T1 (hr) | Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije | |
| KR102275447B1 (ko) | ω3 지방산의 자기 유화 조성물 | |
| JP6835664B2 (ja) | 脂肪酸油混合物の被覆型カプセル剤および錠剤 | |
| KR102488648B1 (ko) | ω3 지방산의 자기 유화 조성물 | |
| JP6151314B2 (ja) | ω３脂肪酸の自己乳化組成物 | |
| HRP20160446T1 (hr) | Farmaceutski pripravci koji sadrže derivat kamptotecina | |
| JP2015520235A5 (hr) | ||
| NZ600720A (en) | A Seamless Capsule For A Liquid Pharmaceutical Composition | |
| JP2013508296A5 (hr) | ||
| HRP20171431T1 (hr) | Terapijska parenteralna primjena krilovog ulja | |
| WO2010117873A3 (en) | Progesterone solutions for increased bioavailability | |
| JP5820256B2 (ja) | 自己乳化製剤 | |
| JP2013508348A5 (hr) | ||
| MX369477B (es) | Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación. | |
| RU2011139638A (ru) | Сублингвальная фармацевтическая композиция, содержащая нейтральное масло | |
| RU2015102597A (ru) | Липидные композиции рацекадотрила | |
| JP2015516418A5 (hr) | ||
| AU2016324349A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
| JP2016512828A (ja) | ラセカドトリル脂質組成物 | |
| RU2010120706A (ru) | Композиция липоевой кислоты в виде шариков | |
| Pandit et al. | Hollow pessary loaded with lawsone via self-microemulsifying drug delivery system for vaginal candidiasis | |
| JP2011006380A (ja) | ω３脂肪酸の乳化組成物 | |
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir | |
| AU2011200677A1 (en) | Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration | |
| ES2944572T3 (es) | Procedimiento de tratamiento de la obesidad |